MAPT and Alzheimer disease: On the other hand, Bouwman et al (72) reported an increase in Aβ1-42 and t-tau (but not p-tau) during AD progression, while two other studies indicated a decrease in Aβ1-42 in AD patients and in p-tau in the late stages of the disease (73,74).